Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.9632 -0.0138 (-1.41%)
Streaming Delayed Price Updated: 12:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd. 
Via Benzinga
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com
Via ACCESSWIRE
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
Via ACCESSWIRE
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)
Via AB Newswire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for... 
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction
Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. 
Via Benzinga
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
Via ACCESSWIRE
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
From Clearmind Medicine Inc.
Via GlobeNewswire
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
Psychedelics biotech firm Clearmind Medicine Inc. 
Via Benzinga
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.